MKS Instruments Is Attractive At Current Levels, Analyst Says

Needham analyst James Ricchiuti maintained MKS Instruments Inc (NASDAQ:MKSI) with a Buy and raised the price target from $90 to $110. At…
  • Needham analyst James Ricchiuti maintained MKS Instruments Inc (NASDAQ:MKSI) with a Buy and raised the price target from $90 to $110.
  • At its analyst day, MKS made the most compelling case for acquiring Atotech, reassuring investors that debt reduction is a priority while providing a reasonable long-term model with several potential areas of upside, characteristic of MKS’s conservative approach.
  • Ricchiuti came away more constructive on the Atotech business, including gaining a better appreciation of the technology differentiation and market strength of having a specialty chemistry business, a plating equipment business, and PCB laser manufacturing technology under one roof. 
  • Investors will better appreciate the complementary nature of the Atotech business with MKS’s PCB laser drilling and high-density interconnect business over the next year. 
  • The business combination provided incremental opportunities and increased content in the high-growth EV market. As a result of the acquisition, MKS increased exposure to the global automotive market at a time when the industry steadily transitioned to electrification, Ricchiuti writes.
  • Electronics & Packaging will likely be the fastest-growing segment of MKS’s business.
  • Shares have underperformed the market and industry peers in 2022, which the analyst attributed to the extended time it took to close the Atotech acquisition during unprecedented interest rate hikes. 
  • The analyst maintained estimates for Q4’22 and 2023 and has introduced the 2024 forecast. MKS is attractive at current levels, Ricchiuti wrote. 
  • Price Action: MKSI shares traded lower by 2.62% at $83.12 on the last check Thursday.
Total
0
Shares
Related Posts
Read More

Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential…

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug AdministrationIf Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLDAcceptance of BLA Will Trigger $20 Million Milestone Payment

ATRA